The takeover deal – terms of which were not made public – will see Dinensione’s trial management, biostatistics, market access capabilities and 40-strong workforce merged with TFS’ existing services offerings.
Ricard Quingles, regional managing director, South Europe at TFS said: “Following several years of collaboration between our companies, the integration of Dimensione within the TFSGroup is a natural further step.
This was echoed by Montse Barcelo, Executive European VP at TFS, who said: “The timing of the investment is ideal, our biotech- and midsized Pharma customers’ need for experienced oncology sites is growing and the Italian University Hospitals are well known worldwide in this therapeutic area.
“The late stage trial phases, increasingly being asked for by our customers, requires a presence on the Italian market for successful pre- and post-launches. With the Dimensione acquisition, we have gained a highly experienced project management team and a local regulatory group.”